Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study
Main finding · PERRResult — go to the resultχ2 3.965Authors' conclusion
This study reported for the first time the effectiveness of combined belimumab therapy in a Chinese cohort of patients with cLN.
Study context
- Population
- Children aged 5–17 years with newly diagnosed childhood-onset LN (cLN), Chinese cohort
- Participants
- 101 children
- Comparison
- Initial combination with belimumab vs standard immunotherapy
- Belimumabn = 38
- Standard immunotherapyn = 63reference
- Outcome
- Primary efficacy renal response (PERR)
- Follow-up
- 12 months
Methodological detailssingle-centre
- Single-centre
Main finding
PERR
χ2
3.965
P = 0.046
By group
As reported in the abstract
Secondary outcomes
CRR · 12 months
χ2 4.679 · P = 0.031
LLDAS · 12 months
χ2 27.84 · P < 0.001
DORIS remission · 12 months
χ2 6.626 · P = 0.01
GC dose ≤7.5 mg/day
χ2 19.737 · P < 0.001
- SLE Disease Activity Index (SLEDAI) and glucocorticoid (GC) dose reduction
- P < 0.05
SLEDAI and GC dose reduction
- Faster and greater reductions in SLEDAI and GC dose with belimumab
Safety
| Outcome | Belimumab | Standard immunotherapy |
|---|---|---|
| eGFR decline of 30% or more · 12 monthsNo worsening of renal function in belimumab group | 0 events | 6.3% |
Serious adverse events
- None reported in either group
Infection
- No significant difference between groups
Original publication
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study. Lupus Sci Med. Published 15 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →